GRM2 and Huntington disease: For instance, genetic ablation of mGluR5 in BACHD model of Huntington’s disease enhances the cortical microglial population whereas pharmacological activation of mGluR2/3 in zQ175 mouse model of Huntington’s disease reduces the striatal microglia numbers [34, 97].